375 470

Cited 15 times in

Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

 Ji Yong Jang  ;  Sang Hak Lee  ;  Byung Soo Kim  ;  Hong Seog Seo  ;  Woo Shik Kim  ;  Youngkeun Ahn  ;  Nae Hee Lee  ;  Kwang Kon Koh  ;  Tae Soo Kang  ;  Sang Ho Jo  ;  Bum Kee Hong  ;  Jang Ho Bae  ;  Hyoung Mo Yang  ;  Kwang Soo Cha  ;  Bum Soo Kim  ;  Choong Hwan Kwak  ;  Deok Kyu Cho  ;  Ung Kim  ;  Joo Hee Zo  ;  Duk Hyun Kang  ;  Wook Bum Pyun  ;  Kook Jin Chun  ;  June Namgung  ;  Tae Joon Cha  ;  Jae Hyeon Juhn  ;  YeiLi Jung  ;  Yangsoo Jang 
 KOREAN CIRCULATION JOURNAL, Vol.45(3) : 225-233, 2015 
Journal Title
Issue Date
Blood pressure ; Controlled clinical trials, randomized ; Drug therapy, combination ; Rosuvastatin ; Valsartan
BACKGROUND AND OBJECTIVES: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. SUBJECTS AND METHODS: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. RESULTS: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. CONCLUSION: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
Files in This Item:
T201502092.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Sang Hak(이상학) ORCID logo https://orcid.org/0000-0002-4535-3745
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Jang Ji Yong(장지용)
Hong, Bum Kee(홍범기) ORCID logo https://orcid.org/0000-0002-6456-0184
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.